Hoth Therapeutics Inc (NASDAQ: HOTH), a biopharmaceutical company, has signed a contract with Voltron Therapeutics Inc to establish a joint venture named HaloVax that is to start preclinical studies for the development of vaccine prospects to prevent the Coronavirus, it was reported on Monday.
The vaccine is being developed based on VaxCelerate, a self-assembling vaccine platform licensed by Voltron from the Vaccine and Immunotherapy Center at Massachusetts General Hospital.
With the support of Massachusetts General Hospital, both firms, will work jointly on exploring and developing this self-assembling vaccine technology as a means to aid patients at risk of being infected with COVID-19. The VaxCelerate vaccine platform was developed as a means of rapidly generating and pre-clinically testing a new vaccine against specific pathogen targets. The technology has received funding from Department of Defense and has demonstrated proof of concept in Lassa fever, an emerging infectious disease. HaloVax aims to use these same self-assembling vaccine principles to assist in the development of a potential vaccine against the COVID-19 pandemic.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer